Search

Your search keyword '"Kang, Rhee-Hun"' showing total 23 results
Start Over Author "Kang, Rhee-Hun"
23 results on '"Kang, Rhee-Hun"'

12. The neural substrates of affective face recognition in patients with Hwa-Byung and healthy individuals in Korea

Author

Lee, Byeong-Taek, primary, Paik, Jong-Woo, additional, Kang, Rhee-Hun, additional, Chung, Sun-Yong, additional, Kwon, Ho-In, additional, Khang, Hyun-Soo, additional, Lyoo, In Kyoon, additional, Chae, Jeong-Ho, additional, Kwon, Jung-Hye, additional, Kim, Jong-Woo, additional, Lee, Min-Soo, additional, and Ham, Byung-Joo, additional

Published
2009
Full Text
View/download PDF

20. Influence of the serotonin transporter promoter gene polymorphism on susceptibility to posttraumatic stress disorder

Author

Lee, Heon-Jeong, primary, Lee, Min-Soo, additional, Kang, Rhee-Hun, additional, Kim, Hyun, additional, Kim, Soon-Duck, additional, Kee, Baik-Seok, additional, Kim, Young Hoon, additional, Kim, Yong-Ku, additional, Kim, Jung Bum, additional, Yeon, Byung Kil, additional, Oh, Kang Seob, additional, Oh, Byung-Hoon, additional, Yoon, Jin-Sang, additional, Lee, Chul, additional, Jung, Han Yong, additional, Chee, Ik-Seung, additional, and Paik, In Ho, additional

Published
2005
Full Text
View/download PDF

22. Association of the adrenergic alpha 2a receptor −1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder

Author

Lee, Hwa-Young, Kang, Rhee-Hun, Paik, Jong-Woo, Jeong, Yoo Jung, Chang, Hun Soo, Han, Sang-Woo, and Lee, Min-Soo

Subjects
*ALPHA adrenoceptors, *CENTRAL nervous system, *DRUG antagonism, *GENETIC polymorphisms, *ANTIDEPRESSANTS, *MENTAL depression, *THERAPEUTICS, *DEPRESSED persons, *WEIGHT gain
Abstract

Abstract: Background: Adrenergic α2a receptors (ADRA2A) are expressed in the central nervous system and peripheral tissues. The primary mechanism of action of mirtazapine is the antagonism of central presynaptic α2 receptors. Mirtazapine is reportedly associated with weight gain. Our objective was to determine whether the ADRA2A −1291C/G polymorphism is associated with weight gain and treatment response to mirtazapine in patients with major depressive disorder (MDD). Methods: The ADRA2A −1291C/G polymorphism was analyzed in 314 MDD patients and 162 control subjects. All patients were evaluated using the 21-item Hamilton Depression Rating Scale at the beginning of the study and at 1, 2, 4, and 8 weeks of mirtazapine treatment. Results: No relationship was observed between the ADRA2A −1291C/G polymorphism and MDD. No significant difference was found between responder and non-responder groups when comparing the ADRA2A genotype distribution with treatment response to mirtazapine. Repeated measures ANOVA with the last observation carry-forward test indicated that after adjusting for baseline body weight, age, and gender, the subjects with the C/C genotype exhibited a greater mean body weight gain than the subjects with the C/G or G/G genotype after 8 weeks of mirtazapine treatment (p =0.052). Conclusions: The ADRA2A −1291C/G polymorphism does not appear to be a predictor of treatment response to mirtazapine. This polymorphism was weakly associated with weight change after 8 weeks of mirtazapine treatment. Further investigation is required to determine whether other polymorphisms of this gene influence treatment response and weight change in patients receiving mirtazapine. [Copyright &y& Elsevier]

Published
2009
Full Text
View/download PDF

23. Effects of CYP2D6and CYP3A5Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients

Author

Kang, Rhee-Hun, Jung, Sun-Min, Kim, Kyoung-Ah, Lee, Duk-Ki, Cho, Hyun-Kee, Jung, Bong-Joo, Kim, Young-Ku, Kim, Seung-Hyun, Han, Changsu, Lee, Min-Soo, and Park, Ji-Young

Abstract

This study was conducted to evaluate the effects of the CYP2D6and CYP3A5genotypes on the steady-state plasma levels of risperidone (RIS), 9-hydroxyrisperidone (9-OH-RIS), and the active moiety (RIS plus 9-OH-RIS) in Korean schizophrenic patients. Sixty-four Korean schizophrenic patients were enrolled. CYP2D6and CYP3A5genotypes were determined, and the plasma levels of RIS and 9-OH-RIS were measured using high-performance liquid chromatography. The dose-normalized plasma concentrations of RIS, 9-OH-RIS, and the active moiety were compared according to the CYP2D6and CYP3A5genotypes. Among the patients, 57 were CYP2D6extensive metabolizers (EMs; CYP2D61/1, 1/10, and 10/10) and 7 were CYP2D6poor metabolizers (PMs; CYP2D61/5and 10/5). For the CYP3A5genotype, 30 patients were CYP3A51expressors (1/1n = 1 and 1/3n = 29) and 34 patients were CYP3A5nonexpressors (3/3). The plasma levels of RIS (2.03 ng/mL per milligram for EMs vs 5.57 ng/mL per milligram for PMs, P< 0.001) and 9-OH-RIS (5.06 ng/mL per milligram for EMs vs 0.22 ng/mL per milligram for PMs, P< 0.001) were significantly different among CYP2D6genotype groups, but the CYP2D6EMs (7.09 ng/mL per milligram) and PMs (5.79 ng/mL per milligram) did not show no difference in the levels of the active moiety (P= 0.470). CYP3A5nonexpressors exhibited higher plasma concentrations of both RIS and 9-OH-RIS than its expressors. In the case of 9-OH-RIS, CYP3A5nonexpressors exhibited significantly higher concentrations than CYP3A5expressors (5.42 vs 3.51 ng/mL per milligram, P= 0.022). In addition, concentrations of the active moiety were also significantly different between the CYP3A5nonexpressors (8.39 ng/mL per milligram) and expressors (5.30 ng/mL per milligram, P= 0.005). In conclusion, both CYP2D6and CYP3A5genotypes affected plasma levels of RIS and 9-OH-RIS, whereas the active moiety levels were influenced only by the CYP3A5genotype but not by the CYP2D6genotype.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results